Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Diabetes Reports
Erschienen in: Current Diabetes Reports 12/2015

01.12.2015 | Pathogenesis of Type 2 Diabetes and Insulin Resistance (RM Watanabe, Section Editor)

Is Insulin Resistance a Feature of or a Primary Risk Factor for Cardiovascular Disease?

verfasst von: Markku Laakso

Erschienen in: Current Diabetes Reports | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

The two major pathophysiological abnormalities in type 2 diabetes are insulin resistance and impaired insulin secretion. Insulin resistance is a general term meaning that insulin does not exert its normal effects in insulin-sensitive target tissues, such as skeletal muscle, adipose tissue, and liver, the major target tissues for insulin action in glucose metabolism. Insulin resistance (IR) promotes cardiovascular disease via multiple mechanisms, including changes in classic cardiovascular risk factors and downregulation of the insulin signaling pathways in different tissues. This review presents evidence for the association of insulin resistance with cardiovascular disease from clinical and population-based studies. The causality of the association of insulin resistance with cardiovascular disease is discussed on the basis of recent findings from the Mendelian randomization studies.
Literatur
1.
DeFronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–95.PubMedCentralCrossRefPubMed
2.
Tripathy D, Almgren P, Tuomi T, et al. Contribution of insulin-stimulated glucose uptake and basal hepatic insulin sensitivity to surrogate measures of insulin sensitivity. Diabetes Care. 2004;27:2204–10.CrossRefPubMed
3.
Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin dependent diabetes mellitus. Prospective studies of Pima Indians. New Engl J Med. 1993;329:1988–92.CrossRefPubMed
4.
5.
Zierath JR, Kawano Y. The effect of hyperglycaemia on glucose disposal and insulin signal transduction in skeletal muscle. Best Pract Res Clin Endocrinol Metab. 2003;17:385–98.CrossRefPubMed
6.
Abdul-Ghani MA, Matsuda M, DeFronzo RA. Strong association between insulin resistance in liver and skeletal muscle in non-diabetic subjects. Diabet Med. 2008;25:1289–94.PubMed
7.
Cherrington AD. Banting lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes. 1999;48:1198–214.CrossRefPubMed
8.
9.
Gastaldelli A, Natali A, Vettor R, et al. Insulin resistance, adipose depots and gut: interactions and pathological implications. Dig Liver Dis. 2010;42:310–9.CrossRefPubMed
10.
11.
DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214–23.PubMed
12.
Knuuti J, Nuutila P. PET as a cardiovascular and metabolic research tool. Ann Med. 1999;31:450–6.CrossRefPubMed
13.
Bergman RN, Ider YZ, Bowden CR, et al. Quantitative estimation of insulin sensitivity. Am J Physiol. 1979;236:E667–77.PubMed
14.
Hanley AJ, Wagenknecht LE, Norris JM, et al. Insulin resistance, beta cell dysfunction and visceral adiposity as predictors of incident diabetes: the insulin resistance atherosclerosis study (IRAS) family study. Diabetologia. 2009;52:2079–86.PubMedCentralCrossRefPubMed
15.
Stančáková A, Javorsky M, Kuulasmaa T, et al. Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men. Diabetes. 2009;58:1212–21.PubMedCentralCrossRefPubMed
16.
Muniyappa R, Lee S, Chen H, et al. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008;294:E15–26.CrossRefPubMed
17.
Vangipurapu J, Stančáková A, Pihlajamäki J, et al. Association of indices of liver and adipocyte insulin resistance with 19 confirmed susceptibility loci for type 2 diabetes in 6,733 non-diabetic Finnish men. Diabetologia. 2011;54:563–71.CrossRefPubMed
18.
Laakso M, Sarlund H, Salonen R, et al. Asymptomatic atherosclerosis and insulin resistance. Arterioscler Thromb. 1991;11:1068–76.CrossRefPubMed
19.
Bressler P, Bailey SR, Matsuda M, et al. Insulin resistance and coronary artery disease. Diabetologia. 1996;39:1345–50.CrossRefPubMed
20.
Zethelius B, Lithell H, Hales CN, et al. Insulin sensitivity, proinsulin and insulin as predictors of coronary heart disease. A population-based 10-year, follow-up study in 70-year old men using the euglycaemic insulin clamp. Diabetologia. 2005;48:862–7.CrossRefPubMed
21.
Wiberg B, Sundström J, Zethelius B, et al. Insulin sensitivity measured by the euglycemic insulin clamp and proinsulin levels as predictors of stroke in elderly men. Diabetologia. 2009;52:90–6.CrossRefPubMed
22.
23.
Laakso M. Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. J Intern Med. 2001;249:225–35.CrossRefPubMed
24.
Gast KB, Tjeerdema N, Stijnen T, et al. Insulin resistance and risk of incident cardiovascular events in adults without diabetes: meta-analysis. PLoS One. 2012;7, e52036.PubMedCentralCrossRefPubMed
25.
Eddy D, Schlessinger L, Kahn R, et al. Relationship of insulin resistance and related metabolic variables to coronary artery disease: a mathematical analysis. Diabetes Care. 2009;32:361–6.PubMedCentralCrossRefPubMed
26.
Yki-Järvinen H, Koivisto VA. Natural course of insulin resistance in type I diabetes. N Engl J Med. 1986;315:224–30.CrossRefPubMed
27.
Cleland SJ, Fisher BM, Colhoun HM, et al. Insulin resistance in type 1 diabetes: what is ‘double diabetes’ and what are the risks? Diabetologia. 2013;56:1462–70.PubMedCentralCrossRefPubMed
28.
Laakso M, Kuusisto J. Insulin resistance and hyperglycemia in cardiovascular disease development. Nat Rev Endocrinol. 2014;10:293–302.CrossRefPubMed
29.
Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: “double diabetes” in the Diabetes Control and Complications Trial. Diabetes Care. 2007;30:707–12.CrossRefPubMed
30.
Schauer IE, Snell-Bergeon JK, Bergman BC, et al. Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: the CACTI study. Diabetes. 2011;60:306–14.PubMedCentralCrossRefPubMed
31.
DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia. 2010;53:1270–87.PubMedCentralCrossRefPubMed
32.
Laakso M. Cardiovascular disease in type 2 diabetes, from population to man to mechanisms: the Kelly West Award Lecture 2008. Diabetes Care. 2010;33:442–9.PubMedCentralCrossRefPubMed
33.
Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Foundation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5.CrossRefPubMed
34.
Kuusisto J, Lempiäinen P, Mykkänen L, et al. Insulin resistance syndrome predicts coronary heart disease events in elderly type 2 diabetic men. Diabetes Care. 2001;24:1629–33.CrossRefPubMed
35.
36.
Carmienke S, Freitag MH, Pischon T, et al. General and abdominal obesity parameters and their combination in relation to mortality: a systematic review and meta-regression analysis. Eur J Clin Nutr. 2013;67:573–85.CrossRefPubMed
37.
Fall T, Hägg S, Mägi R, et al. The role of adiposity in cardiometabolic traits: a Mendelian randomization analysis. PLoS Med. 2013;10, e1001474.PubMedCentralCrossRefPubMed
38.
39.
Van de Voorde J, Pauwels B, Boydens C, et al. Adipocytokines in relation to cardiovascular disease. Metabolism. 2013;62:1513–21.CrossRefPubMed
40.
41.
Michael MD, Kulkarni RN, Postic C, et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell. 2000;6:87–97.CrossRefPubMed
42.
Obstfeld AE, Sugaru E, Thearle M, et al. C-C chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis. Diabetes. 2010;9:916–25.CrossRef
43.
Adiels M, Olofsson SO, Taskinen MR, et al. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28:1225–36.CrossRefPubMed
44.
Borén J, Taskinen MR, Olofsson SO, et al. Ectopic lipid storage and insulin resistance: a harmful relationship. J Intern Med. 2013;274:25–40.CrossRefPubMed
45.
Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363:1341–50.CrossRefPubMed
46.
FízeIova M, Cederberg H, Stančáková A, et al. Markers of tissue-specific insulin resistance predict the worsening of hyperglycemia, incident type 2 diabetes and cardiovascular disease. PLoS One. 2014;9, e109772.CrossRef
47.
48.
de Jager J, Dekker JM, Kooy A, et al. Endothelial dysfunction and low-grade inflammation explain much of the excess of cardiovascular mortality in individuals with type 2 diabetes: the Hoorn Study. Arterioscler Thromb Vasc Biol. 2006;26:1086–93.CrossRefPubMed
49.
Paré G, Ridker PM, Rose L, et al. Genome-wide association analysis of soluble ICAM-1 concentration reveals novel associations at the NFKBIK, PNPLA3, RELA, and SH2B3 loci. PLoS Genet. 2011;7, e1001374.PubMedCentralCrossRefPubMed
50.
Soinio M, Marniemi J, Laakso M, et al. High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-up study. Diabetes Care. 2006;29:329–33.CrossRefPubMed
51.
Elliott P, Chambers JC, Zhang W, et al. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA. 2009;302:37–48.PubMedCentralCrossRefPubMed
52.
Wensley F, Gao P, Burgess S, et al. Association between C reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data. BMJ. 2011;342:d548.CrossRefPubMed
53.
Han S, Liang CP, DeVries-Seimon T, et al. Macrophage insulin receptor deficiency increases ER stress-induced apoptosis and necrotic core formation in advanced atherosclerotic lesions. Cell Metab. 2006;3:257–66.CrossRefPubMed
54.
Myoishi M, Hao H, Minamino T, et al. Increased endoplasmic reticulum stress in atherosclerotic plaques associated with acute coronary syndrome. Circulation. 2007;116:1226–33.CrossRefPubMed
55.
56.
Jansen H, Samani NJ, Schunkert H. Mendelian randomization studies in coronary artery disease. Eur Heart J. 2014;35:1917–24.CrossRefPubMed
57.
58.
Hanieh Yaghootkar H, Scott RA, White CC, et al. Genetic evidence for a normal-weight “metabolically obese” phenotype linking insulin resistance, hypertension, coronary artery disease, and type 2 diabetes. Diabetes. 2014;63:4369–77.CrossRefPubMed
59.
Kilpeläinen TO, Zillikens MC, Stančákova A, et al. Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. Nat Genet. 2011;43:753–60.PubMedCentralCrossRefPubMed
60.••
Ross S, Gerstein HC, Eikelboom J, et al. Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease. Eur Heart J. 2015;36:1454–62. This study is the first one to show that dysglycemia, diabetes, insulin resistance, and impaired insulin secretion are causally associated with the risk of coronary heart disease.CrossRefPubMed
61.
Benn M, Tybjaerg-Hansen A, McCarthy MI, et al. Nonfasting glucose, ischemic heart disease, and myocardial infarction: a Mendelian randomization study. J Am Coll Cardiol. 2012;59:2356–65.PubMedCentralCrossRefPubMed
62.•
Nordestgaard BG, Palmer TM, Benn M, et al. The effect of elevated body mass index on ischemic heart disease risk: causal estimates from a Mendelian randomisation approach. PLoS Med. 2012;9:e1001212. The first Mendelian randomization study showing that obesity is causally associated with the risk of ischemic heart disease.PubMedCentralCrossRefPubMed
63.
Holmes MV, Lange LA, Palmer T, et al. Causal effects of body mass index on cardiometabolic traits and events: a Mendelian randomization analysis. Am J Hum Genet. 2014;94:198–208.PubMedCentralCrossRefPubMed
64.
Hägg S, Fall T, Ploner A, et al. Adiposity as a cause of cardiovascular disease: a Mendelian randomization study. Int J Epidemiol. 2015;44:578–86.CrossRefPubMed
65.
Lieb W, Jansen H, Loley C, et al. Genetic predisposition to higher blood pressure increases coronary artery disease risk. Hypertension. 2013;61:995–1001.CrossRefPubMed
66.
Mahendran Y, Cederberg H, Vangipurapu J, et al. Glycerol and fatty acids in serum predict the development of hyperglycemia and type 2 diabetes in Finnish men. Diabetes Care. 2013;36:3732–8.PubMedCentralCrossRefPubMed
67.
De Silva NM, Freathy RM, Palmer TM, et al. Mendelian randomization studies do not support a role for raised circulating triglyceride levels influencing type 2 diabetes, glucose levels, or insulin resistance. Diabetes. 2011;60:1008–18.PubMedCentralCrossRefPubMed
68.••
Do R, Willer CJ, Schmidt EM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45:1345–52. The authors used 185 common variants mapped for plasma lipids to examine the role of triglycerides in risk for coronary heart disease. Their results suggest that triglyceride-rich lipoproteins causally influence risk for coronary heart disease.PubMedCentralCrossRefPubMed
69.
Deloukas P, Kanoni S, Willenborg C, et al. Large-scale association analysis identified new risk loci for coronary heart disease. Nat Genet. 2013;45:25–33.CrossRefPubMed
70.
Haase CL, Tybjærg-Hansen A, Nordestgaard BG, et al. High-density lipoprotein cholesterol and risk of type 2 diabetes: a Mendelian randomization study. Diabetes. 2015.
71.
Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet. 2012;380:572–80. This study demonstrates the causality of LDL cholesterol in the risk of myocardial infarction using a Mendelian randomization approach. The study also showed that low HDL cholesterol was not causally associated with the risk of myocardial infarction.PubMedCentralCrossRefPubMed
72.
Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, et al. Genetically elevated lipoprotein (a) and increased risk of myocardial infarction. JAMA. 2009;22:2331–9.CrossRef
73.
Sarwar N, Butterworth AS, Freitag DF, et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;9822:1205–13.
74.
Nüesch E, Dale C, Palmer TM, et al. Adult height, coronary heart disease and stroke: a multi-locus Mendelian randomization meta-analysis. Int J Epidemiol. 2015.
75.
Holmes MV, Dale CE, Zuccolo L, Silverwood RJ, et al. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ. 2014;10(349):g4164.CrossRef
76.
Codd V, Nelson CP, Albrecht E, et al. Identification of seven loci affecting mean telomere length and their association with disease. Nat Genet. 2013;45:422–7.PubMedCentralCrossRefPubMed
Metadaten
Titel
Is Insulin Resistance a Feature of or a Primary Risk Factor for Cardiovascular Disease?
verfasst von
Markku Laakso
Publikationsdatum
01.12.2015
Verlag
Springer US
Erschienen in
Current Diabetes Reports / Ausgabe 12/2015
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-015-0684-4

Weitere Artikel der Ausgabe 12/2015

Current Diabetes Reports 12/2015 Zur Ausgabe

Health Care Delivery Systems and Implementation in Diabetes (EB Morton-Eggleston, Section Editor)

Mobile Phone and Smartphone Technologies for Diabetes Care and Self-Management

Pathogenesis of Type 1 Diabetes (A Pugliese, Section Editor)

Towards an Earlier and Timely Diagnosis of Type 1 Diabetes: Is it Time to Change Criteria to Define Disease Onset?

Health Care Delivery Systems and Implementation in Diabetes (EB Morton-Eggleston, Section Editor)

Health Systems Approaches to Diabetes Screening and Prevention in Women with a History of Gestational Diabetes

Diabetes Epidemiology (NM Maruthur, Section Editor)

Betatrophin in Diabetes Mellitus: the Epidemiological Evidence in Humans

Microvascular Complications—Neuropathy (R Pop-Busui, Section Editor)

Retinal Failure in Diabetes: a Feature of Retinal Sensory Neuropathy

Microvascular Complications—Retinopathy (JK Sun, Section Editor)

Hypoxia and Dark Adaptation in Diabetic Retinopathy: Interactions, Consequences, and Therapy

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Gegen postoperative Darmmotilitätsstörung: Erster Kaffee schon im Aufwachraum

30.04.2024 DCK 2024 Kongressbericht

Nach einer Operation kann es zu einer vorübergehenden Störung der Darmmotilität kommen, ohne dass es eine mechanische Ursache gibt. Auf eine postoperative Darmmotilitätsstörung weist besonders hin, wenn Nahrung oral nicht toleriert wird.

Frauen bekommen seltener eine intensive Statintherapie

30.04.2024 Statine Nachrichten

Frauen in den Niederlanden erhalten bei vergleichbarem kardiovaskulärem Risiko seltener eine intensive Statintherapie als Männer. Ihre LDL-Zielwerte erreichen sie aber fast ähnlich oft.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise